FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385837115> ?p ?o ?g. }

• W4385837115 endingPage "B001" @default.
• W4385837115 startingPage "B001" @default.
• W4385837115 abstract "Abstract Introduction. Clear cell renal cell carcinoma (ccRCC) is a highly vascularized and clinically aggressive cancer. In the UK, there are around 9000 diagnoses and 3000 deaths annually. Targeted therapies that inhibit angiogenic regulators, such as bevacizumab (monoclonal antibody which inhibits vascular endothelial growth factor A, VEGF-A), have limited efficacy due to drug resistance. Expression of calcitonin receptor-like receptor (CLR) is upregulated in ccRCC and correlates with disease outcome. The expression of adrenomedullin (AM), peptide agonist of CLR and angiogenic factor, is upregulated in ccRCC. We hypothesized that the CLR signaling axis acts as an alternative pathway that enables resistance to drugs targeting the VEGF-A pathway in ccRCC. In the present study, we aimed to determine whether this signaling axis remains active in VEGF-A-stimulated and bevacizumab-treated human endothelial cells. Methods. Primary human dermal blood vessel endothelial cells (HDBEC; PromoCell) were characterized by immunofluorescence utilizing pan-endothelial (cluster of differentiation 31 and 144, CD31 and CD144, and von Willebrand factor, vWF) and lymphatic-specific (lymphatic vessel endothelial hyaluronan receptor 1, LYVE-1, and prospero homeobox 1, PROX1) markers and confocal microscopy. The activities of CLR agonists (AM; intermedin, IMD; calcitonin gene-related peptide, CGRP; 10−12 - 10−6 M at 10 min) and VEGF-A (50 ng/ml over 30-minute time course) were measured by analyzing phosphorylation of p44/42 mitogen-activated protein kinases (MAPK) using immunoblotting. HDBEC were pre-treated with bevacizumab or human IgG1 at 250 ng/ml and then stimulated with individual CLR agonists at 10−6 M for 10 minutes. Experiments were repeated at least three times. Data were analyzed using Shapiro-Wilk normality, unpaired statistics and appropriate multiple comparisons tests utilizing GraphPad Prism and p&lt;0.05 interpreted as significant. Results. HDBEC were a pure population. AM, IMD and CGRP induced p44/42 MAPK phosphorylation at 10−6 M (p&lt;0.05). For all three CLR agonists and VEGF-A, p44/42 MAPK phosphorylation peaked after 10 minutes of incubation (p&lt;0.05). Bevacizumab treatment at 250 ng/ml was sufficient to inhibit VEGF-A-induced p44/42 MAPK phosphorylation (p&lt;0.05). AM, IMD and CGRP were all able to induce phosphorylation of p44/42 MAPK after bevacizumab treatment (p&lt;0.01). Conclusions. The findings that CLR agonists induce p44/42 MAPK phosphorylation in VEGF-A-stimulated HDBEC after bevacizumab treatment support our hypothesis. This work provides a foundation for investigating the role of the CLR signaling axis in mechanisms of ccRCC resistance to drugs targeting the VEGF-A pathway. Citation Format: Matthew A. Morfitt, John Greenman, Anthony Maraveyas, Leonid L. Nikitenko. Calcitonin receptor-like receptor agonists induce p44/42 MAPK phosphorylation in VEGF-A-stimulated human blood endothelial cells after bevacizumab treatment [abstract]. In: Proceedings of the AACR Special Conference: Advances in Kidney Cancer Research; 2023 Jun 24-27; Austin, Texas. Philadelphia (PA): AACR; Cancer Res 2023;83(16 Suppl):Abstract nr B001." @default.
• W4385837115 created "2023-08-16" @default.
• W4385837115 creator A5017413865 @default.
• W4385837115 creator A5060816944 @default.
• W4385837115 creator A5078637552 @default.
• W4385837115 creator A5092641741 @default.
• W4385837115 date "2023-08-15" @default.
• W4385837115 modified "2023-10-03" @default.
• W4385837115 title "Abstract B001: Calcitonin receptor-like receptor agonists induce p44/42 MAPK phosphorylation in VEGF-A-stimulated human blood endothelial cells after bevacizumab treatment" @default.
• W4385837115 doi "https://doi.org/10.1158/1538-7445.kidney23-b001" @default.
• W4385837115 hasPublicationYear "2023" @default.
• W4385837115 type Work @default.
• W4385837115 citedByCount "0" @default.
• W4385837115 crossrefType "journal-article" @default.
• W4385837115 hasAuthorship W4385837115A5017413865 @default.
• W4385837115 hasAuthorship W4385837115A5060816944 @default.
• W4385837115 hasAuthorship W4385837115A5078637552 @default.
• W4385837115 hasAuthorship W4385837115A5092641741 @default.
• W4385837115 hasConcept C126322002 @default.
• W4385837115 hasConcept C134018914 @default.
• W4385837115 hasConcept C146285616 @default.
• W4385837115 hasConcept C14858245 @default.
• W4385837115 hasConcept C167734588 @default.
• W4385837115 hasConcept C2776694085 @default.
• W4385837115 hasConcept C2777025900 @default.
• W4385837115 hasConcept C2777802072 @default.
• W4385837115 hasConcept C2780394083 @default.
• W4385837115 hasConcept C502942594 @default.
• W4385837115 hasConcept C71924100 @default.
• W4385837115 hasConceptScore W4385837115C126322002 @default.
• W4385837115 hasConceptScore W4385837115C134018914 @default.
• W4385837115 hasConceptScore W4385837115C146285616 @default.
• W4385837115 hasConceptScore W4385837115C14858245 @default.
• W4385837115 hasConceptScore W4385837115C167734588 @default.
• W4385837115 hasConceptScore W4385837115C2776694085 @default.
• W4385837115 hasConceptScore W4385837115C2777025900 @default.
• W4385837115 hasConceptScore W4385837115C2777802072 @default.
• W4385837115 hasConceptScore W4385837115C2780394083 @default.
• W4385837115 hasConceptScore W4385837115C502942594 @default.
• W4385837115 hasConceptScore W4385837115C71924100 @default.
• W4385837115 hasIssue "16_Supplement" @default.
• W4385837115 hasLocation W43858371151 @default.
• W4385837115 hasOpenAccess W4385837115 @default.
• W4385837115 hasPrimaryLocation W43858371151 @default.
• W4385837115 hasRelatedWork W1686147318 @default.
• W4385837115 hasRelatedWork W2080421696 @default.
• W4385837115 hasRelatedWork W2097382995 @default.
• W4385837115 hasRelatedWork W2154502317 @default.
• W4385837115 hasRelatedWork W2556830543 @default.
• W4385837115 hasRelatedWork W2754287291 @default.
• W4385837115 hasRelatedWork W2966595418 @default.
• W4385837115 hasRelatedWork W4235333461 @default.
• W4385837115 hasRelatedWork W2189479065 @default.
• W4385837115 hasRelatedWork W29305073 @default.
• W4385837115 hasVolume "83" @default.
• W4385837115 isParatext "false" @default.
• W4385837115 isRetracted "false" @default.
• W4385837115 workType "article" @default.